Loading...
Market
When will ArsenalBio receive FDA approval for its next product?
2
Resolution / Starting Odds
Q4 2024 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Later • 25%
Official FDA announcements and ArsenalBio press releases
Story
ArsenalBio Raises $325M in Series C, One of 2024's Largest Biotech Funding Rounds
Sep 4, 2024, 02:33 PM
ArsenalBio has successfully raised $325 million in a Series C financing round, marking one of the largest biotech funding rounds of the year. This investment will support the company's ongoing development efforts and scale its manufacturing capabilities for T-cell medicines. The funding round ranks as the fourth largest biotech raise of 2024, following Xaira Therapeutics' $1 billion, Mirador Therapeutics' $400 million, and Formation Bio's $372 million. ArsenalBio expressed gratitude to both new and existing investors for their support.
View original story
Similar markets
Yes • 50%
No • 50%
Q1 2026 • 25%
Q2 2026 • 25%
Q3 2026 • 25%
Q4 2026 or later • 25%
Approval • 33%
Rejection • 33%
Request for more data • 34%
Yes • 50%
No • 50%
Q4 2024 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 or later • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Rejection • 25%